Shock Anxiety among Implantable Cardioverter Defibrillator Recipients with Recent Tachyarrhythmia

Morken, Ingvild Margreta; Isaksen, Kjetil; Karlsen, Bjørg; Norekvål, Tone M.; Bru, Edvin; Larsen, Alf Inge

doi:10.1111/j.1540-8159.2012.03505.x

Cited by 32 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 To this purpose, we selected 3 standard questionnaire surveys to be completed by patients. [12][13][14][15][16][17] Not unexpectedly, the more ICD-specific FSAS survey found a modest association between device discharges and elevated levels of anxiety, presumably the fear and anticipation of future uncomfortable arrhythmia-triggered ICD interventions. However, the HADS subpanels and SF12 v.2 survey found little evidence of excessive impairment in general psychological well-being.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators

Maron

Casey

Olivotto

et al. 2018

Circ: Arrhythmia and Electrophysiology

View full text Add to dashboard Cite

BACKGROUND:High-risk patients with hypertrophic cardiomyopathy (HCM) are identified by contemporary risk stratification and effectively treated with implantable cardioverter-defibrillators (ICDs). However, long-term HCM clinical course after ICD therapy for ventricular tachyarrhythmias is incompletely understood. METHODS AND RESULTS:Cohort of 486 high-risk HCM patients with ICDs was assembled from 8 international centers. Clinical course and device interventions were addressed, and survey questionnaires assessed patient anxiety level and psychological well-being related to ICD therapy. Of 486 patients, 94 (19%) experienced appropriate ICD interventions terminating ventricular tachycardia/ventricular fibrillation, 3.7% per year for primary prevention, over 6.4±4.7 years. Of 94 patients, 87 were asymptomatic or only mildly symptomatic at the time of appropriate ICD interventions; 74 of these 87 (85%) remained in classes I/II without significant change in clinical status over the subsequent 5.9±4.9 years (up to 22). Among the 94 patients, there was one sudden death (caused by device failure; 1.1%); 3 patients died from other HCM-related processes unrelated to arrhythmic risk (eg, end-stage heart failure). Post-ICD intervention, freedom from HCM mortality was 100%, 97%, and 92% at 1, 5, and 10 years, distinctly lower than in ischemic or nonischemic cardiomyopathy ICD trials. HCM patients with ICD interventions reported heightened anxiety in expectation of future shocks, but with intact general psychological well-being and quality of life. CONCLUSIONS:In HCM, unlike ischemic heart disease, prevention of sudden death with ICD therapy is unassociated with significant increase in cardiovascular morbidity or mortality, or transformation to heart failure deterioration. ICD therapy does not substantially impair overall psychological and physical well-being.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[12][13][14] The Florida Shock Anxiety Scale (FSAS) survey consists of 10 items that respondents rate on a 5-point scale from 1 to 5. Higher values represent greater shock anxiety.…”

Section: Florida Shock Anxiety Scalementioning

confidence: 99%

Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators

Maron

Casey

Olivotto

et al. 2018

Circ: Arrhythmia and Electrophysiology

View full text Add to dashboard Cite

show abstract

“…Poziom stresu może być różny, ale u pacjentów mogą też występować bardziej nasilone postaci choroby, takie jak zespół stresu pourazowego [232,233], który wiąże się z wcześniejszymi wyładowaniami oraz stresem przed wszczepieniem ICD [234]. U pacjentów z niedawną tachyarytmią może również występować lęk w oczekiwaniu na kolejne wyładowanie [235]. Większą skłon-ność do występowania tych problemów po wszczepieniu ICD wykazują pacjenci z dużym nasileniem obaw dotyczących ICD przed implantacją, a depresja w tej populacji może być szczególnie niebezpieczna [236,237].…”

Section: Psychospołeczne Następstwa Leczenia Za Pomocą Implantowanychunclassified

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Priori

Blomström‐Lundqvist²,

Mazzanti³

et al. 2015

Kardiol Pol

Self Cite

233

337

View full text Add to dashboard Cite

“…13 The functional class was self-reported according to the New York Heart Association (NYHA) classification 14 on the validated Norwegian version of this instrument. 15 QoL was reported by the validated Minnesota Living with Heart Failure Questionnaire (MLHFQ), which quantifies how patients with HF perceive their own QoL associated with the HF symptoms and treatment the preceding month. The questionnaire consists of 21 items where the patients are asked to rate how each item prevents them from living the life they desire using a sixpoint Likert scale from 0 to 5 (0= not at all, 5= all the time).…”

Section: Patient-reported Outcome Measuresmentioning

confidence: 99%

Patient-reported outcomes and associations with pleural effusion in outpatients with heart failure: an observational cohort study

et al. 2017

View full text Add to dashboard Cite

ObjectivesWe aimed to study whether patient-reported outcomes, measured by quality of life (QoL) and functional class, are sensitive to pleural effusion (PLE) in patients with heart failure (HF), and to study changes in QoL and functional class during follow-up of PLE.MethodsA cohort of 62 patients from an outpatient HF clinic was included. The amount of PLE was quantified using a pocket-sized ultrasound imaging device. Self-reports of QoL and functional class were collected using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the New York Heart Association (NYHA) functional classification.ResultsAt baseline, 26 (42%) patients had PLE of which 19 (31%) patients had moderate to severe amounts of PLE. Patients with no to mild PLE had a lower MLHFQ score (mean 42, SD 21) compared with patients with a moderate to severe amount of PLE (mean 55, SD 24), p=0.03. For 28 patients (45%) with follow-up data, we observed a linear improvement of the MLHFQ-score (3.2, 95% CI 1.2 to 5.1) with each centimetre reduction of PLE. Correspondingly, patient-reported NYHA-class followed the same pattern as the MLHFQ-score.ConclusionsOur study indicates that patient-reported outcome measures as MLHFQ may be sensitive tools to identify patients with HF at highest risk of symptomatic PLE and that treatment targeting reduction of PLE during follow-up is essential to improvement of QoL and functional capacity of outpatients with HF.Trial registration numberNCT01794715; Results

show abstract

Shock Anxiety among Implantable Cardioverter Defibrillator Recipients with Recent Tachyarrhythmia

Cited by 32 publications

References 41 publications

Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators

Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Patient-reported outcomes and associations with pleural effusion in outpatients with heart failure: an observational cohort study

Contact Info

Product

Resources

About